UBS downgraded Medpace stock to 'Sell' on July 30, 2025. TD Cowen analyst also downgraded Medpace stock on the same date.
2 reports, 1 independent
Updated Jul 30
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
UBS downgraded Medpace stock to 'Sell' on July 30, 2025. TD Cowen analyst also downgraded Medpace stock on the same date.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Medpace CEO provided commentary on the company's Q2 performance on July 28, 2025.Sub-event
UBS and TD Cowen downgraded Medpace stock to 'Sell' on July 30, 2025.1 source
Keep exploring
The entities involved
-
Medpace
medical Services Corporation
-
UBS
Swiss multinational investment bank and financial services company
-
TD Cowen
American investment bank
Related events
Coverage
Newest first; wire copies grouped- StockStoryWhy Medpace (MEDP) Stock Is Trading Lower Today Shares of clinical research company Medpace Holdings (NASDAQ:MEDP) fell 3.3% in the morning session after UBS downgraded the stock to 'Sell' from 'Neut
- StockStoryMedpace (MEDP) Stock Trades Down, Here Is Why Shares of clinical research company Medpace Holdings (NASDAQ:MEDP) fell 7.5% in the afternoon session after an analyst at TD Cowen downgraded the stock t